13 Best Growth Stocks to Buy Right Now

In this article, we will discuss the 13 Best Growth Stocks to Buy Right Now.

On March 16, Chief Investment Strategist at Hightower Stephanie Link and Chief Investment Officer at NFJ Investment Group John Mowrey joined CNBC to discuss oil shocks and market opportunities. Link suggested that while markets may remain in a trading range until there is visibility regarding the Strait of Hormuz, investors should take advantage of current dislocations. She noted that those who sold during Liberation Day missed a 34% rally and advised buying fundamentally strong stocks on weakness.

Mowrey concurred with Link’s opportunistic stance and highlighted potential gains in smaller-cap names that have been disproportionately affected by interest rate concerns. Mowery made a distinction between shock inflation caused by a sudden spike in oil prices and hot inflation driven by a broad economic overheat. He argued that because policymakers are more likely to look through shock inflation, investors should remain bullish, anticipating a significant relief rally once the immediate crisis passes. He notes that while WTI crude briefly crossed $100 per barrel, technology stocks are becoming increasingly attractive as their multiples compress into the low 20s despite CAGR exceeding 30%.

Our Methodology

We used screeners to identify stocks that have a track record of delivering earnings growth and have grown their EPS by at least 20% over the past 3 years. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.

Note: All data was sourced on March 17. 

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

13 Best Growth Stocks to Buy Right Now

13. Palisade Bio Inc. (NASDAQ:PALI)

Palisade Bio Inc. (NASDAQ:PALI) is one of the best growth stocks to buy right now. On February 23, Palisade Bio presented translational data from its Phase 1b study of PALI-2108. The findings highlight that this once-daily oral prodrug, designed for targeted delivery to the terminal ileum and colon, achieved localized target engagement and clinical response within 7 days in patients with moderate-to-severe ulcerative colitis.

The data showed a 100% clinical response rate and a 40% clinical remission rate based on modified Mayo Scores, supported by a safety profile across 89 total subjects with no serious adverse events or treatment discontinuations. Mechanism-of-action data derived from colon tissue RNA sequencing confirmed that PALI-2108 successfully suppresses inflammatory and fibrotic gene programs. The results were accompanied by reduced mucosal PDE4B expression, increased tissue cAMP levels, and decreased inflammatory cell signatures. These pharmacologic effects were concentrated in the colonic tissue, while peripheral immune profiles remained largely unchanged, validating the drug’s localized activity.

PALI-2108 uses local bacterial bioactivation to ensure the PDE4 inhibitor remains inactive until it reaches the lower intestine. This targeted approach is engineered to prevent upper gut absorption and minimize peak plasma levels, thereby reducing common systemic side effects such as nausea, headache, and diarrhea. Palisade Bio Inc. (NASDAQ:PALI) believes the convergence of clinical response, tissue pharmacodynamics, and gene expression modulation de-risks the program as PALI-2108 moves into later-stage clinical development.

Palisade Bio Inc. (NASDAQ:PALI) operates as a clinical-stage biopharmaceutical company that develops and advances novel therapeutics for autoimmune, inflammatory, and fibrotic diseases.

12. Blend Labs Inc. (NYSE:BLND)

Blend Labs Inc. (NYSE:BLND) is one of the best growth stocks to buy right now. On March 3, Blend Labs announced the launch of Blend Autopilot, which is an AI agent integrated into its digital origination platform designed to complete loan reviews in as little as 15 seconds. This tool addresses the traditional mortgage cycle, which often spans 30 to 60 days, by reviewing borrower documents and application data in real time.

While the agent automates document parsing, compliance checks, and the generation of follow-up tasks, it remains a non-decisioning tool that leaves all final credit determinations to human underwriters and automated underwriting systems. The technology aims to eliminate the delay between borrower action and lender response, particularly since over half of borrower interactions occur outside of standard business hours.

When a borrower uploads a document or completes an application section, Blend Autopilot immediately cross-references the data against specific lender guidelines and triggers automated workflows. Blend Autopilot is currently available in a preview phase for all Blend platform customers and can be activated via a single toggle in the Lending Config Center without a dedicated implementation project. This agent represents the first in a planned series of AI tools that Blend Labs Inc. (NYSE:BLND) intends to introduce across the entire origination lifecycle.

Blend Labs Inc. (NYSE:BLND) is a technology company that offers a cloud-based software platform for financial services firms. It provides products that power digital-first consumer journeys, such as deposit services and specialized homeownership enhancement tools.

11. ADC Therapeutics (NYSE:ADCT)

ADC Therapeutics (NYSE:ADCT) is one of the best growth stocks to buy right now. On March 10, ADC Therapeutics reported its financial and operational results for Q4 and the full-year 2025, highlighting upcoming clinical milestones for its lead product, ZYNLONTA. The company recorded Q4 net product revenue of $22.3 million and full-year revenue of $73.6 million, driven by stable demand and higher selling prices. With $261.3 million in cash and cash equivalents as of December 31, 2025, the company expects its current cash runway to extend at least into 2028.

The company is approaching several value-creating catalysts in its clinical pipeline, specifically targeting diffuse large B-cell lymphoma/DLBCL. Topline data from the LOTIS-5 Phase 3 confirmatory trial is expected in Q2 2026, with full results for both LOTIS-5 and the LOTIS-7 Phase 1b trial anticipated by year-end. If these results are positive, the company plans to pursue sBLA and potential compendia inclusions in 2027. Additionally, investigator-initiated trials are evaluating ZYNLONTA for other B-cell malignancies, including follicular lymphoma and marginal zone lymphoma, with data expected between late 2026 and mid-2027.

Financial performance for 2025 showed a significant reduction in net loss, which totaled $142.6 million for the full year compared to $157.8 million in 2024. This improvement was attributed to lower R&D expenses following the discontinuation of certain programs and a reprioritization initiated in June 2025. Total adjusted operating expenses also decreased year-over-year as ADC Therapeutics (NYSE:ADCT) optimized its organizational structure.

ADC Therapeutics (NYSE:ADCT) is a healthcare company that offers an antibody drug conjugate/ADC technology platform with flagship products that include ZYNLONTA, which is a CD19-directed ADC.

10. LiveRamp Holdings Inc. (NYSE:RAMP)

LiveRamp Holdings Inc. (NYSE:RAMP) is one of the best growth stocks to buy right now. On March 3, LiveRamp announced the launch of new agentic AI upgrades to its data collaboration platform, designed to automate marketing workflows such as audience planning, spend optimization, and performance measurement. These updates allow specialized AI agents to collaborate autonomously across the marketing ecosystem within a governed environment.

Available in alignment with organizational AI policies, these capabilities aim to replace manual, fragmented processes with intelligent execution to drive exponential performance gains for brands and partners. The platform now supports licensed third-party agents, including those from Newton Research and SemantIQ, which integrate directly into the LiveRamp hub. These partnerships are intended to streamline the end-to-end marketing cycle, enabling marketers to act on data insights with greater speed and scalability.

In addition to agent integration, LiveRamp Holdings Inc. (NYSE:RAMP) introduced flexible tools for precision growth, such as enhanced lookalike modeling across first, second, and third-party data. These upgrades also include the ability to apply single identity-powered control groups across multiple channels for consistent performance measurement. By addressing traditional friction points in data connectivity and workflow, these tools help advertisers scale reach and optimize experimentation.

LiveRamp Holdings Inc. (NYSE:RAMP) is a technology company that operates the LiveRamp Data Collaboration platform to help organizations unify customer and prospect data to build a single view of the customer to protect consumer privacy.

9. Arcutis Biotherapeutics Inc. (NASDAQ:ARQT)

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the best growth stocks to buy right now. On March 10, Arcutis Biotherapeutics announced the publication of long-term Phase 3 data regarding ZORYVE (roflumilast) cream 0.05% for children aged 2 to 5 with mild-to-moderate atopic dermatitis. The INTEGUMENT-OLE study, which followed patients for up to 52 weeks, showed that the once-daily nonsteroidal treatment is safe and well-tolerated, with efficacy that consistently improved over the course of the year.

These findings supported the FDA approval of the 0.05% strength in October 2025, providing a durable option for a pediatric population that often faces limited long-term therapy choices. The study results showed that 63.1% of children who completed 56 weeks of treatment achieved ‘Clear’ or ‘Almost Clear’ skin, and over 70% reached a 75% reduction in their Eczema Area and Severity Index score.

A significant subset of participants who achieved total skin clearance were transitioned to a proactive twice-weekly maintenance regimen; these children sustained disease control for a median duration of ~8 months. Caregivers also reported substantial improvements in itch, with over 57% of patients showing a significant reduction in itch intensity by the study’s conclusion. Regarding safety, the treatment exhibited a favorable profile with most adverse events being mild to moderate, such as upper respiratory tract infections and nasopharyngitis.

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) develops and commercializes treatments for dermatological diseases. Its lead product is a topical roflumilast cream for plaque psoriasis & atopic dermatitis, called ZORYVE.

8. Atour Lifestyle Holdings Limited (NASDAQ:ATAT)

Atour Lifestyle Holdings Limited (NASDAQ:ATAT) is one of the best growth stocks to buy right now. On March 17, Atour Lifestyle Holdings announced financial results for Q4 and the full-year 2025, marking the completion of its ‘2,000 Premier Hotels’ initiative. As of December 31, 2025, the company’s hotel network expanded to 2,015 hotels in operation, a 24.5% year-over-year increase, with an additional 779 manachised hotels currently under development.

While the hotel sector saw rapid expansion, the company’s retail business emerged as a significant growth engine, with full-year retail revenue surging 67% to reach RMB3.67 billion. Full-year net revenues increased by 35.1% to RMB9.79 billion, while net income rose 27.4% to RMB1.62 billion. For Q4 specifically, net income saw a sharp 44.7% increase compared to the previous year. Although hotel operational metrics like occupancy (75.9%) and RevPAR (RMB340) showed slight year-over-year declines for the full year, the overall scale of the network and the high-margin retail contributions supported adjusted EBITDA, which grew 40% to reach RMB2.48 billion in 2025.

For 2026, Atour Lifestyle Holdings Limited (NASDAQ:ATAT) launched a new 3-year strategic plan titled ‘Chinese Experience, Brand-Led Excellence’. This plan focuses on deepening emotional connections with users through human-centered services and high-quality products. With a solid cash position of RMB3.3 billion and a debt balance of only RMB252 million as of year-end, the company aims to use its brand leadership in the sleep market and its expanded hotel footprint to navigate future industry cycles.

Atour Lifestyle Holdings Limited (NASDAQ:ATAT) is a lodging company that develops lifestyle brands around hotel offerings in China, providing hotel management services and selling hotel supplies & other products.

7. Sportradar Group (NASDAQ:SRAD)

Sportradar Group (NASDAQ:SRAD) is one of the best growth stocks to buy right now. On March 3, Sportradar reported earnings for 2025, with revenue increasing 17% to €1,290 million. The company generated €100 million in profit for the period compared to the previous year, supported by a 33% rise in Adjusted EBITDA to €297 million. This growth was fueled by strong performance in the US market, which grew 23% year-over-year, and a customer net retention rate of 109%.

A major highlight was the completion of the IMG ARENA acquisition in November 2025, which integrated a global sports betting rights portfolio covering over 70 rights holders. This acquisition was structured to include $225 million in total financial consideration from the seller, intended to be accretive to margins and free cash flow. Throughout the year, Sportradar also extended its exclusive data partnership with MLB for 8 years and secured new rights with FIFA and the German DFB Cup. These moves helped the company expand its annual coverage to over 1 million sporting events across the globe.

For 2026, Sportradar Group (NASDAQ:SRAD) targets revenue growth of 23% to 25% on a constant currency basis. The company expects Adjusted EBITDA to reach a range of €390 million to €400 million, reflecting an anticipated margin expansion of over 200 basis points. With a strong liquidity position of €585 million and no debt outstanding as of year-end 2025, the company is positioned to continue its aggressive share buyback strategy while integrating new AI-driven fan engagement products, such as the 4Sight data overlay developed for NBC Universal.

Sportradar Group (NASDAQ:SRAD) is a software application company that provides sports data services for the sports betting & media industries and offers betting technology & solutions.

6. Klaviyo Inc. (NYSE:KVYO)

Klaviyo Inc. (NYSE:KVYO) is one of the best growth stocks to buy right now. On March 9, Klaviyo and Shopify (NASDAQ:SHOP) announced a deepened product integration designed to streamline global expansion for enterprise retailers. This collaboration centers on the launch of Locale Aware Catalogs, a feature that natively synchronizes Shopify Markets’ localized data (including translated content, regional pricing, and currency) directly into Klaviyo’s CRM.

By unifying these data foundations, the partnership aims to eliminate the manual workarounds previously required to manage separate regional catalogs, allowing brands to maintain a single global strategy with hyperlocal execution. The integration uses Klaviyo Inc.’s (NYSE:KVYO) AI-powered tools to automate personalized customer experiences across multiple markets.

New capabilities include automated localized content for email and SMS, smart regional filtering that restricts product recommendations to local availability, and unified workflows that adapt a single marketing template to a customer’s specific language and location. This technical alignment ensures that every customer touchpoint, from product links to support content in the Customer Hub, remains consistent with the specific Shopify Markets settings for that shopper.

Klaviyo Inc. (NYSE:KVYO) is a tech company that provides a cloud-based SaaS platform for entrepreneurs, small & medium-sized businesses, mid-market businesses, and enterprises.

Click to continue reading and see the 5 Best Growth Stocks to Buy Right Now.

Disclosure: None. None. Follow Insider Monkey on Google News.